Fortress Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.18 per share for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2022-03-28
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.00.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $2.15, a 14.36% increase year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $1.88, a 37.23% increase year-over-year.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $1.18, a 0.00% change from fiscal 2019.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $1.18.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $1.37, a 36.28% decline from fiscal 2015.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $2.15, a 16.85% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.18 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $1.18 10-Q · filed 2020-11-09 | |||
| 2019-12-31 | $1.18 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $1.18 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.18 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | |||
| 2017-06-30 | $1.37 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $1.37 10-K · filed 2018-03-16 | |||
| 2015-12-31 | $2.15 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $2.15 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $2.15 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $2.15 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $1.84 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $1.84 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $1.84 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $1.88 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $1.76 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $1.70 10-Q · filed 2013-11-01 | |||
| 2013-06-30 | $1.56 10-Q · filed 2013-08-05 | |||
| 2013-03-31 | $1.37 10-Q · filed 2013-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |